Amgen sees exec shakeup

Facing investors unhappy over an unimpressive stock price and its R&D wing being pared down to reduce the bite it takes out of revenue, Amgen announced yesterday that both its CEO and R&D chief are leaving. Kevin Sharer (photo) will step down May 23, and Roger Perlmutter will hand CMO Sean Harper the research reins in February. Meanwhile, COO Bob Bradway will become chief executive. The pair of moves is widely interpreted as a shakeup at the top. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.